Evaluating liver safety early in drug development is critical to reducing risk and downstream failure. By incorporating flow, multi-cellular architecture, and tunable microenvironments, microphysiological systems (MPS) — also known as organ-on-a-chip models — better reflect human liver biology than conventional static assays. These capabilities support improved prediction of drug-induced liver injury (DILI), species translation, and chronic exposure studies.
Download this Technology Guide to learn:
- Key considerations for adopting MPS to assess DILI
- How to adapt and scale MPS for evolving research needs
- Mechanisms of hepatotoxicity and biomarkers commonly assessed using MPS
